Revascularization and cardioprotective drug treatment in myocardial infarction patients: how do they impact on patients' survival when delivered as usual care

Table 2 Characteristics of MI patients according to exposure to revascularization and medication (n = 5596)

	Total	Men	Women	Age (years) Mean (± SD)	Comorbidity index Mean (± SD)
Revascularization
No	4473	2505 (56.0%)^a	1968 (44.0%)	76.2 (± 7.2)^b	1.7 (± 1.8)^b
Yes	1123	701 (62.4%)	422 (37.6%)	72.0 (± 5.2)	1.3 (± 1.5)
PTCA	767	470 (61.3%)	297 (38.7%)	72.1 (± 5.4)	1.1 (± 1.4)
CABG	356	231 (64.9%)	125 (35.1%)	71.6 (± 4.7)	1.5 (± 1.6)
Number of drug classes
0	757	413 (54.6%)^c	344 (45.4%)	76.3 (± 8.0)^b	2.0 (± 1.9)^b
1	1166	682 (58.5%)	484 (41.5%)	76.5 (± 7.1)	1.8 (± 1.8)
2	2046	1190 (58.2%)	856 (41.8%)	75.4 (± 6.9)	1.6 (± 1.8)
3	1315	741 (56.3%)	574 (43.7%)	74.0 (± 6.4)	1.4 (± 1.6)
4	312	180 (57.7%)	132 (42.3%)	73.4 (± 5.6)	1.5 (± 1.6)

^a The difference between rates of men according to revascularization is statistically significant (p = 0.0003)
^b The differences between means (age and Comorbidity index) according to revascularization and number of drug classes are all statistically significant (p < .0001)
^c The difference between rates of men according to number of drug classes is not statistically significant (p = 0.3889)

ISSN: 1471-2261